Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Our new book is a comprehensive look at a vital part of medicines development and regulatory affairs. Grab your copy today!
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
This is an On-demand recording from August 2021.
In chemistry, manufacturing, and controls (CMC) regulatory writing, there is a difference in the level of detail required for New Drug Applications (NDAs) and Biologic License Application (BLAs) supporting different types of products. The expectations tend to diminish as time elapses and the regulatory authority becomes more familiar with a specific type of medicinal product. Small molecule oral solid products have been submitted to and approved by regulatory authorities more frequently and represent a different set of expectations than are expected for vaccines and biologics. Vaccines and biologics tend to be rather comparable to each other yet they contain significant differences in requirements for certain modules. This program investigates the differences between the small molecule NDA, and the biologic and vaccine BLA. It will tie together the processes required for small molecules, biologics, and vaccines, including relevant information in a company’s regulatory applications, including pertinent regulatory guidelines and the synthesis, production, and/or manufacturing of the compounds and products.
This event is brought to you by Certara .
Upon the conclusion of the program you will:
This webcast will provide a high-level overview of the expectations required for Module 3 submissions for a small molecule oral solid product NDA, a parenteral biologic BLA, and a vaccine BLA. The program will start with the small molecule oral solid, progress to the biologic including a brief discussion of post approval changes, and finish with the vaccine.
Intermediate: Content is designed based upon the assumption that individuals have basic knowledge of the topic(s) and/or demonstrated competence related to the topic(s). Higher-level concepts are introduced during lectures; exercises requiring synthesis and/or application of concepts are incorporated into the activity.
Recently, there have been significant changes in the requirements around human factors for medical devices. This workshop will provide practical guidance and information for:
Nellie Waterland Forwood has more than 30 years of experience in the pharmaceutical industry (pre- and postapproval) as a CMC regulatory affairs professional. She is a certified Six Sigma Master Black Belt with proven expertise in the use of Six Sigma define, measure, analyze, improve, and control tools to improve processes and implement and maintain improvements. As a principal regulatory writer, Forwood has written various types of pharmaceutical CMC and clinical regulatory documents. She has experience in documentation preparation for pre-meeting briefing documents, Investigational New Drug Applications (INDs), Investigational Medicinal Product Dossiers (IMPDs), NDAs, and Marketing Authorisation Applications (MAAs) for large and small molecules with emphasis on regulations and electronic Common Technical Document (eCTD) requirements. Forwood also has experience in writing Clinical Study Protocols (CSPs) and Investigator’s Brochures (IBs).
James M. Zoshak is an experienced CMC regulatory project manager, writer, and strategist, with more than 15 years of experience. In his role, he plans, organizes, writes, reviews, and edits CMC regulatory submissions and other relevant documentation in support of the registration of numerous small molecule, biopharmaceutical, and gene therapy products marketed across the globe. In addition, he worked on site as the primary liaison to one of Synchrogenix’s largest clients for ten years, and continues to liaise with Synchrogenix’s clients to ensure consistent, high quality support. Zoshak is familiar with all major market regulatory submission types, both pre- and postapproval, and has experience with assembling international dossiers. He also prepares responses to health authority questions; briefing packages for major submissions, FDA type C meetings, and European scientific advice meetings; and white papers on regulatory strategy and the science behind biologics and gene therapies. He has additionally been responsible for the construction and maintenance of submission libraries, dossier conformance guides, and databases tracking the interactions of global change control, supplement, and supporting documentation.
As an Associate Principal Regulatory Writer, Dr. Waterland has extensive medical writing experience in the authoring, reviewing, and editing of pre and post-approval regulatory documents for submission to Global Health Authorities; his primary specialty is authoring and reviewing of submission level Chemistry, Manufacturing, and Controls (CMC) documents for monoclonal antibody biologic drugs, vaccines, and other large molecule products.